Aethlon Medical to Present at Italian Embassy Avian and Human Influenza Pandemic Conference.

SAN DIEGO -- Aethlon Medical, Inc., (OTCBB:AEMD) a pioneer in developing therapeutic devices for infectious disease, announced today that Mr. James A. Joyce, CEO and Chairman of Aethlon Medical, Inc., will present at the plenary session on Research and Development at the Italian Embassy in Washington, DC, this Friday October 6th at 11:30 am EST.

The conference will provide an opportunity to hear from leading European and U.S. experts on research, policy, development and the psychology of the avian flu and bioterror global health challenge. The conference, coordinated by the Italian Embassy, will be held in partnership with the French Embassy and the European Commission Delegation. Featured participants include Anthony S. Fauci, Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, U.S. Department of Health and Human Services and other domestic and international authorities on pandemic treatment, organization and response.

"Aethlon Medical is honored to have been invited to take part in this prestigious event," stated Mr. Joyce. "I look forward to meeting with, sharing plans, and exchanging ideas with many of the world's foremost medical and operational thought leaders in the bioterror and pandemic response arena," continued Mr. Joyce. "I believe our Hemopurifier(TM) technology will play an important role in the treatment of present and evolving pandemic threats," concluded Joyce.

About Aethlon Medical

Aethlon Medical has developed the first-in-class medical device to treat infectious disease. The device, known as the Hemopurifier(TM), is a broad-spectrum treatment countermeasure against drug and vaccine resistant bioweapons, naturally evolving pandemic threats such as H5N1 Avian Flu, and chronic infectious disease targets including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Global researcher, Frost & Sullivan, recently awarded the Hemopurifier(TM) the 2006 Technology Innovation Award for its advances in the field of biodefense. Aethlon has also initiated research on a second generation Hemopurifier(TM) that targets the capture of growth factors inherent in the spread of Cancer. More information on Aethlon Medical and the Hemopurifier(TM) technology can be found at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.